2016 Article "Hematological Cancers Industry" Research Report, Market value, Global Review
Hematological malignancies are a class of cancer that affect the blood, lymph nodes and bone marrow. They include numerous forms of leukemia, lymphoma and myeloma. Hematological malignancies constituted 9% of all newly diagnosed malignancies in the US in 2011, with data indicating lymphomas are more prevalent than leukemias or myeloma. Excluding acute lymphocytic leukemia and Hodgkin’s lymphoma, these types of malignancy are generally associated with increasing age. Therefore, considering the aging population globally, this class of malignancy is likely to become more prevalent.
To Browse a Report Detail with TOC @ http://www.researchmoz.us/global-hematological-cancers-market-to-2022-commercially-successful-targeted-therapies-and-large-innovative-pipeline-to-drive-market-report.html
Over the past 15 years, the treatment of hematological malignancies has changed significantly, with the development of targeted therapies. These developments were based on the growing understanding of the signaling pathways involved in disease pathogenesis. Notable examples include the approval of rituximab in 1997, which is used to treat multiple types of hematological malignancies, including Non-Hodgkin’s lymphoma.
Overall, there are 1,207 products in active development in the hematological cancer therapy area. The indications included in this disease cluster are classified under oncology, which is the largest therapy area in terms of pipeline products, consisting of 6,936 drugs in development. Hematological cancer has more active pipeline products than the respiratory and cardiovascular therapy areas, which indicates how active this disease cluster is in terms of product development.
The hematological cancers market is characterized by commercially successful therapies.
Which classes of drug dominate the market?
What additional benefits have newly approved therapies brought to the market?
How do the leading marketed therapies compare clinically?
The pipeline contains a range of molecule types and molecular targets, with a strong emphasis on targeted therapies, as opposed to chemotherapeutic agents.
Which molecular targets appear most frequently in the pipeline?
What are the commercial prospects for the most promising late-stage pipeline products?
Hematological cancers clinical trials have an overall attrition rate of 70.3%.
What are the failure rates at individual Phases of clinical development?
How do leukemia, lymphoma and myeloma compare in terms of clinical trial failure rate?
To Free Sample Report With TOC @ http://www.researchmoz.us/enquiry.php?type=S&repid=725318
The hematological cancers market is forecast to rise from a value of $30.7 billion in 2015 to $70.1 billion in 2022, at a CAGR of 12.5%.
How much of a role will disease prevalence and new product approvals play in market growth?
Will generic competition have a significant impact on the market over the forecast period?
Big pharma hold a notable presence in the market.
What are the leading companies in terms of market share?
Which companies are forecast to experience the greatest growth in market share?
What are the drivers of growth for key companies in the market?
How dependent are the key companies on this disease cluster for revenue?
Which companies rely heavily on this disease cluster for revenue?
Reasons to buy
This report will allow you to -
Understand the current clinical and commercial landscape through a comprehensive study of disease pathogenesis, diagnosis, prognosis, and the current treatment landscape in hematological cancers.
Assess the current treatment landscape, with product profiles on prominent marketed therapies, including revenue forecasts.
Analyze the hematological cancers pipeline and stratify by stage of development, molecule type, and molecular target. The most promising late-stage therapies are profiled and assessed in terms of clinical performance and competitiveness, alongside a single-product forecast.
Predict growth in market size, with in-depth market forecasting from 2015 to 2022. The forecasts will provide an understanding of how epidemiology trends, new drug entries, and patent expirations will influence market value.
Identify the leading companies in the market, in terms of market share and growth. Company analysis determines how dependent the key companies in the market are on revenue derived from hematological cancer products. In addition, analysis determines the primary factors that will drive market growth for the key companies in the market.
Identify commercial opportunities in the hematological cancers deals landscape by analyzing trends in licensing and co-development deals, and by profiling the most significant deals that have occurred in this indication in recent years.
Table of Contents
1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 8
2 Introduction 11
2.1 Therapy Area Introduction 11
2.2 Epidemiology 11
2.2.1 Leukemia 12
2.2.2 Lymphoma 13
2.2.3 Myeloma 14
2.3 Pathophysiology 15
2.3.1 Leukemia 15
2.3.2 Lymphoma 16
2.3.3 Myeloma 18
2.4 Symptoms 20
2.5 Diagnosis 20
2.5.1 Leukemia 20
2.5.2 Lymphoma 21
2.5.3 Myeloma 21
2.6 Prognosis and Survival 22
2.6.1 Survival 25
2.7 Treatment 25
2.7.1 Surgery and Radiation Therapy 26
2.7.2 Stem Cell Transplantation 27
2.7.3 Pharmacological Therapies 27
To Enquire Regarding This Report @ http://www.researchmoz.us/enquiry.php?type=E&repid=725318
ResearchMoz is the world’s fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz’s service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.
Researchmoz Pvt. Ltd.,
90 State Street,
Albany, NY 12207,
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release 2016 Article "Hematological Cancers Industry" Research Report, Market value, Global Review here
News-ID: 344341 • Views: 379
More Releases from Researchmoz Global Pvt. Ltd.
Online Fitness Services Market Size, Share, Growth, Trend, Drivers and Restraint …
Online Fitness Services Market is predicted to grow at substantial compounded annual rate of growth (CAGR) during the forecast period 2020-2027. The markets growth is analysed by studying multiple determinants like Market Drivers, Trends, Challenges, Opportunities, Restraints, and Competition. It includes detailed analysis of the market on the basis of competitive profiles of key players, market segmentations, geographical analysis and economic models. The influence of Covid-19 on the market is discussed
Senior Living Market Current Status and Challenges with Future Opportunities to …
The Senior Living Market Report provides a detailed assessment of the market by highlighting information on various aspects including the global market, including drivers, restraints, opportunities, threats and development trends, competitive landscape analysis, and Growth status of key regions. The report provides comprehensive numerical analysis of the Senior Living industry and data for creating strategies to increase market growth and success. The report estimates market size, price, revenue, gross margin
Testing and Inspection Services Market 2020 Analysis includes Growth, Challenges …
The Testing and Inspection Services Market Report provides a detailed assessment of the market by highlighting information on various aspects including the global market, including drivers, restraints, opportunities, threats and development trends, competitive landscape analysis, and Growth status of key regions. The report provides comprehensive numerical analysis of the Testing and Inspection Services industry and data for creating strategies to increase market growth and success. The report estimates market size,
Proctoring Solution for Online Exams Market 2021 Leading Players, Industry Updat …
The study provides an in-depth study of the Proctoring Solution for Online Exams Market's trends and opportunities. On the basis of recent events and historical data, it makes figurative estimates and forecasts the future for the coming years. Moreover, the market document holds a substantial importance when it is about explaining market definition, classifications, applications and engagements. With the study of competitor analysis conducted in this Proctoring Solution for Online
More Releases for Hematological
Advanced Technologies Of Hematological Disorders Market 2017
Albany, NY, 23rd November : Recent research and the current scenario as well as future market potential of "Frontier Pharma: Hematological Disorders - Iron Regulators and Immune Response Targeted Programs Within Anemias and other Red Blood Cell Disorders Hold Potential to Transform Therapy Area with Significant Unmet Need" globally. The hematological disorders therapy area encompasses non-malignant disorders of the blood such as anemia, sickle cell disease, neutropenia and hemophilia. Get PDF for
Hematological Disorders - Pipeline Insight and Therapeutic Assessment Reviewed i …
Market Research Hub (MRH) has recently added a new report on “hematological disorders therapy” area encompasses non-malignant disorders of the blood such as anemia, sickle cell disease, neutropenia and hemophilia. These diseases can be grouped into the three categories- red blood cell disorders, bleeding disorders and immune cell disorders - of which red blood cell disorders are characterized by significant unmet need related to few effective treatment options and poor
Hematological Cancers Market 2017 Trends and Review
The Global Hematological Cancers Market Research Report 2017 to 2022 renders deep perception of the key regional market status of the Hematological Cancers Industry on a global level that primarily aims the core regions which comprises of continents like Europe, North America, and Asia and the key countries such as United States, Germany, China and Japan. Request for sample of Hematological Cancers Market research report @ https://goo.gl/BeUKBz Split by product type,
Hematological Malignancies Market Is Expected To Profits
Global Hematological Malignancies Market: Snapshot Hematological malignancies, commonly known as hematological cancer, is registering a widespread prevalence across the world. According to the National Cancer Institute, hematological cancer is the fifth most commonly occurring cancer, globally, and is the second prominent reason behind the cancer death in the U.S. Researchers expect the incidence of hematological malignancies to increase further in the coming years, which will result in the growing need for
Hematological Malignancies Market grows with growing prevalence of hematological …
The global hematological malignancies market is highly competitive in nature and is characterized by a consolidated nature, owing to the presence of a few players holding a large share of the overall market, states a research study by Transparency Market Research. The leading players operating in the global market, including Roche, Celgene, Novartis, and AbbVie are anticipated to remain dominant throughout the forecast period. In order to maintain their position
Hematological Cancers Market Review with Comparative Analysis
Hematological cancer, commonly known as hematological malignancy, is a class of cancer that affects the lymph nodes, blood, and bone marrow. It includes numerous forms such as lymphoma, leukemia, and myeloma. Leukemia is a malignancy in which abnormal white blood cells are formed in the bone marrow. Lymphoma is a blood cancer that develops in the lymphatic system. Myeloma is a cancer associated with the plasma of the white blood